Praluent · DIN 02453835 · 150 mg/mL · injection solution-pre-filled pen
Limited Use, Reason for Use code 555 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 555 required
Write on scriptReason for Use code 555 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 555
Reason for Use code 555
For the treatment of Heterozygous Familial Hypercholesterolemia (HeFH) in patients 18 years of age or older who meet the following criteria:
1. Definite or probable diagnosis of HeFH using the Simon Broome or Dutch Lipid Network criteria or genetic testing;
AND
2. Unable to reach Low Density Lipoprotein Cholesterol (LDL-C) target (i.e., LDL-C less than 2.0 mmol/L for secondary prevention) or at least a 50% reduction in LDL-C from untreated baseline for primary prevention despite:
A) Confirmed adherence to ezetimibe for at least a total of 3 months in combination with high dose statin (e.g., atorvastatin 80mg or rosuvastatin 40mg);
OR
B) Confirmed adherence to ezetimibe for at least a total of 3 months and inability to tolerate high dose statin defined as:
(i) Inability to tolerate at least 2 statins with at least one started at the lowest starting dose;
(ii) For each statin (two statins in total), dose reduction is attempted for intolerable symptom (myopathy) or biomarker abnormality (creatine kinase (CK) greater than 5 times the upper limit of normal) resolution rather than discontinuation of statin altogether;
(iii) For each statin (two statins in total), intolerable symptoms (myopathy) or abnormal biomarker (creatine kinase (CK) greater than 5 times the upper limit of normal) changes are reversible upon statin discontinuation but reproducible by re-challenge of statins where clinically appropriate; and
(iv) One of the following:
(I.) Other known determinants of intolerable symptoms or abnormal biomarkers have been ruled out;
(II.) Patient developed confirmed and documented rhabdomyolysis;
(III.) Patient is statin contraindicated i.e. active liver disease, unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal.
Treatment with alirocumab should be discontinued if the patient does not meet all of the following:
1. Patient is adherent to therapy.
2. Patient has achieved a reduction in LDL-C of at least 40% from baseline (4-8 weeks after initiation of alirocumab).
3. Patient continues to have a significant reduction in LDL-C (with continuation of alirocumab) of at least 40% from baseline since initiation of PCSK9 inhibitor. LDL-C should be checked periodically with continued treatment with PCSK9 inhibitors (e.g., every 6 months).
Patients prescribed alirocumab 75mg every two weeks must use the 75mg/mL dosage strength and are limited to 26 pre-filled pens (PFP) per year.
Patients prescribed alirocumab 150mg every two weeks must use the 150mg/mL dosage strength and are limited to 26 PFP per year.
Patients prescribed alirocumab 300mg every four weeks may use either the 150mg/mL dosage strength (limited to 26 PFP per year) or the 300mg/2mL dosage strength (limited to 13 PFP per year).
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Praluent · DIN 02453835
Manufacturer: Sanofi-Aventis Canada Inc.; listing date 2019-03-28
Health Canada: Marketed since 2016-04-29 · brand PRALUENT · ATC C10AX14 ALIROCUMAB · form Solution · route Subcutaneous · ingredients ALIROCUMAB 150 MG/ML · company Sanofi-aventis canada inc · schedule Schedule d, Prescription
Praluent: Formulary list price $273.45 per unit (the source does not state the unit; exact figure $273.4500). What the ministry pays, not the patient.
Ministry pays: $273.4500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02453835)
Source record
DIN 02453835: Praluent
Raw flags: sec12=Y, sec3=Y
Item: 240624004; group id 310; item number 0684; lccId 00315; manufacturer id SAC
Source form: Inj Sol-Pref Pen; strength: 150mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $273.4500; ministry $273.4500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453835
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94037
Shortage status: not checked (no credentials)